Active substanceLactic acid + Salicylic acidLactic acid + Salicylic acid
Similar drugsTo uncover
  • Duofilm
    solution externally 
  • Momat-S
    ointment externally 
  • Dosage form: & nbspointment for external use
    Composition:

    In 100 g of ointment contains:

    active substances: mometasone furoate - 0.1 g, salicylic acid -5.0 g.

    Excipients: Vaseline (white petrolatum), beeswax white, propylene glycol monostearate, hexylene glycol.

    Description:Homogeneous ointment of white color.
    Pharmacotherapeutic group:Glucocorticosteroid for topical use + keratolytic agent
    ATX: & nbsp

    D.11.A.F   Preparations for the treatment of calluses and warts

    Pharmacodynamics:

    The pharmacodynamic properties of the Momat-C ointment are directly related to the presence of active components, mometasone furoate and salicylic acid.

    Mometasone furoate is a potent glucocorticosteroid.

    Like other topical glucocorticosteroids, mometasone furoate has anti-inflammatory, antipruritic and vasoconstrictive properties. Glucocorticosteroid induces the release of proteins inhibiting the phospholipase Ar and known under the general name of lipocortins. These proteins control the biosynthesis of such potent inflammatory mediators,as prostaglandins and leukotrienes, by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by the action of phospholipase A2.

    In the experiments in vitro it was shown that mometasone furoate is a potent inhibitor of the synthesis of three cytokines involved in the initiation of the inflammatory process and its maintenance: interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α).

    Salicylic acid causes exfoliation of the stratum corneum and, at the same time, does not lead to qualitative or quantitative changes in the structure of the viable epidermis. This mechanism of action is explained by dissolving the intercellular binder.

    Pharmacokinetics:

    Suction. After a single local application of the ointment containing mometasone furoate (0.1%) in combination with salicylic acid (5%), for 12 hours without an occlusive bandage on the damaged skin, a systemic uptake of approximately 1.5% of the applied dose was found. The average content of salicylic acid in the maximum was 0.0908 mg / dl in the plasma. Systemic toxic reactions to the presence of salicylic acid are usually associated with significantly higher plasma levels (30-40 mg / dl).

    Metabolism. Absorbed mometasone furoate is rapidly metabolized with the formation of a variety of metabolites, which are more polar compounds than the original substance. Metabolites do not have pharmacological activity. The main metabolites of salicylic acid, quantitatively determined in plasma after topical application of the Momat-C ointment, is gentisic acid (CmOh = 0.00127 mg / dL after 24 hours) and salicyluric acid (CmOh = 0.0171 mg / dL after 3.3 hours).

    Excretion. It is excreted mainly by the kidneys and in an insignificant quantity with bile.

    Indications:

    Psoriasis.

    Contraindications:

    Ointment Momat-C is contraindicated in patients with increased sensitivity to mometasone furoate, salicylic acid or to any other component of the drug. Like other topical glucocorticosteroids, Momat-C ointment is not indicated for use by patients suffering from bacterial, viral (herpes simplex, varicella zoster, shingles) or fungal skin infections. The drug should not be used in the treatment of rosacea or perioral dermatitis. In addition, Ointment Momat-C is contraindicated in the treatment of post-vaccination reactions, tuberculosis and syphilis. It is not recommended to use the drug for children under 12 years, for women during pregnancy and lactation.

    Carefully:

    In inflammatory diseases, including peripheral vessels, irritation or infection of the skin and patients receiving large doses of salicylates (for example, in rheumatoid arthritis), patients with diabetes mellitus, glaucoma and cataracts.

    Dosing and Administration:

    Outwardly. A thin layer of ointment should be applied to the affected areas of the skin twice a day, in the morning and in the evening; the maximum daily dose is 15 g.

    Side effects:

    In general, the ointment of Momat-C is well tolerated twice a day. The most common side effects are: mild or moderate burning on the spot, ointment, itching, peeling.

    Of the reported side effects with local corticosteroids on large skin surfaces are the following: irritation, skin maceration, dryness, folliculitis, acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, the appearance of atrophic skin bands, sweating, secondary infections, hypertrichosis. Children can suppress the function of the hypothalamic-pituitary-adrenal system with the development of Cushing's syndrome.

    Overdose:

    Long-term use of topically applied glucocorticosteroids in excessive amounts can lead to suppression of the hypothalamic-pituitary-adrenal system and secondary adrenal insufficiency. If suppression is observed hypothalamic-pituitary-adrenal system, it is necessary to stop using the ointment or reduce the frequency of application.

    In case of toxicity caused by salicylic acid, the use of Momat-C ointment should be discontinued. To stimulate the withdrawal of salicylates in the urine, it is necessary to inject fluids. If necessary, oral or intravenous administration of sodium bicarbonate and potassium salts can be prescribed.

    Interaction:

    With local application of the Momat-C ointment, very small but measurable quantities of salicylates in the blood plasma were observed. According to published data on the interaction of salicylates with other substances after ingestion or application to the skin, it is possible to change the effect of the following medicinal compounds: tolbutamide (butamid), methotrexate, heparin, pyrazinamide, agents that promote the excretion of uric acid and preparations of indirect anticoagulants.Other glucocorticosteroids and ammonium sulfate may affect the salicylic acid content. These interactions should be borne in mind when assigning the Momat-C ointment together with these compounds.

    Special instructions:

    As with all glucocorticosteroid preparations, appropriate precautions should be taken when applying ointment to large areas of the skin or the intended long-term use. This warning is especially important in pediatrics. Due to the fact that the ratio of the skin surface and body weight in children is higher than in adults, children may be more sensitive to the action of glucocorticosteroids than adults, with the appearance of signs of suppression of the hypothalamic-pituitary-adrenal system and the manifestation of Cushing's syndrome.

    Ointment is not recommended for use with occlusive dressings, including diapers and diapers. The preparation is not intended for application to the face or in the groin and axilla regions. Ointment is not to be used in ophthalmology.

    Children should receive the minimum amount of glucocorticosteroids needed to achieve the effect.Long-term therapy with glucocorticosteroids may have an undesirable effect on the growth and development of children.

    In case of irritation, including excessive dryness of the skin and when allergic reactions appear, stop using the Momat-C ointment and prescribe the appropriate treatment.

    If a concomitant skin infection develops, the necessary antifungal or antibacterial agent should be used. If a positive response to treatment is not achieved quickly, the use of the Momat-C ointment should be discontinued until the infection is properly eliminated.

    It is necessary to assess the risk and expected effect of using the Momat-C ointment in the case of the presence of the following diseases: diabetes, peripheral vascular injury or inflammation, irritation or skin infection.

    Glucocorticosteroids can cause a change in the appearance of the affected areas of the skin, which makes it difficult to make the right diagnosis and leads to a slowdown in recovery.

    Effect on the ability to drive transp. cf. and fur:

    It is not found the effect of the drug on the ability to drive and other mechanisms.

    Form release / dosage:Ointment for external use.
    Packaging:For 10 g and 15 g in aluminum lacquered tubes, having a nozzle with a closed end, with a lid having a piercing tip. One tube together with the instruction for use is placed in a cardboard box.
    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Do not freeze.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-003331/09
    Date of registration:30.04.2009
    Expiration Date:Unlimited
    The owner of the registration certificate:Glenmark Pharmaceuticals Co., Ltd.Glenmark Pharmaceuticals Co., Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspGLENMARK IMPEX LLCGLENMARK IMPEX LLCRussia
    Information update date: & nbsp24.06.2016
    Illustrated instructions
      Instructions
      Up